As has been repeatedly shown in studies, including the UK SIGNIFY study in 2017, annual whole-body MRI (WBMRI) can detect cancers early, when they are more treatable, for people with Li Fraumeni Syndrome (LFS). While it has been recommended for people with LFS in the UK, access is patchy across different parts of the NHS – a topic which we have been highlighting for some time now.
The SIGNIFIED project aims to add to the evidence on the value of WBMRI for people with LFS. It will generate data on changes in the quality of life for people with LFS receiving WBMRI, as well as being used to create a model to show that WBMRI is cost-effective and feasible across the whole of the NHS. The study aims to recruit 50 LFS patients over the next 3 months, and to offer them WBMRI, once at the start of the study and a follow-up 12 months later. Participants, who should not have had cancer in the previous 5 years, will also be asked to complete a health questionnaire at each of their scans. The study is based at the Royal Marsden Hospital, but potentially participants may take part in other centres if not close to London.
This study offers an opportunity for participants to gain access to WBMRI, and to help in providing the evidence to support the roll-out of WBMRI across the whole country. If you are interested in taking part, please contact Dr Elena Cojocaru (Elena.cojocaru@rmh.nhs.uk).